Tags

Type your tag names separated by a space and hit enter

Commentary on the effects of RANKL inhibition on bone mass and muscle strength?

Abstract

Osteoporosis and sarcopenia, or interpreted as osteo-sarcopenia, is a major public health problem and the social economic burden in many countries and also in Asia. It's the most common metabolic bone and muscle disorder in elderly, especially in female. Osteoporosis is a pathologic process by a decrease in bone mass and deterioration in skeletal microarchitecture, accompanied by a progressive and generalized loss of muscle mass with muscle strength or a loss of physical performance with increasing rates of disability, poor mobility, frailty, and even the mortality and morbidity. Bone and muscle have been increasingly recognized as interacting tissues as a result of the mechanical effects of muscle loading on bone function. Some endocrine disorders are also related to osteoporosis and sarcopenia, e.g. diabetes mellitus, thyroid dysfunction, vitamin D deficiency, insulin-like growth factor-1, growth hormone, sex hormones, cytokine imbalance, obesity and malnutrition. Bone and muscle dysfunction, also characterized by the predominant atrophy of type II fibers together with smaller and fewer mitochondria, are associated with several genetic polymorphisms of the genes such as α-actinin 3, proliferator-activated receptor gamma coactivator 1-alpha, glycine-n-acyltransferase, methyltransferase-like 21C, myostatin, and myocyte enhancer factor 2C (Fig.1). Therefore, the denervation of single muscle fibers reduces type-II fibers, which are gradually replaced by type-I fibers and adipose tissue.

Authors+Show Affiliations

Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital-Linko, Taoyuan, Taiwan. School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital-Linko, Taoyuan, Taiwan. School of Nursing, College of Medicine, and Healthy Aging Research Center, Chung-Gung University, Taoyuan, Taiwan.Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31633306

Citation

Hwang, Jawl-Shan, et al. "Commentary On the Effects of RANKL Inhibition On Bone Mass and Muscle Strength?" Journal of Diabetes Investigation, 2019.
Hwang JS, Lien SA, Jiang YD. Commentary on the effects of RANKL inhibition on bone mass and muscle strength? J Diabetes Investig. 2019.
Hwang, J. S., Lien, S. A., & Jiang, Y. D. (2019). Commentary on the effects of RANKL inhibition on bone mass and muscle strength? Journal of Diabetes Investigation, doi:10.1111/jdi.13165.
Hwang JS, Lien SA, Jiang YD. Commentary On the Effects of RANKL Inhibition On Bone Mass and Muscle Strength. J Diabetes Investig. 2019 Oct 21; PubMed PMID: 31633306.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Commentary on the effects of RANKL inhibition on bone mass and muscle strength? AU - Hwang,Jawl-Shan, AU - Lien,Shin-Yu Angela, AU - Jiang,Yi-Der, Y1 - 2019/10/21/ PY - 2019/10/22/entrez JF - Journal of diabetes investigation JO - J Diabetes Investig N2 - Osteoporosis and sarcopenia, or interpreted as osteo-sarcopenia, is a major public health problem and the social economic burden in many countries and also in Asia. It's the most common metabolic bone and muscle disorder in elderly, especially in female. Osteoporosis is a pathologic process by a decrease in bone mass and deterioration in skeletal microarchitecture, accompanied by a progressive and generalized loss of muscle mass with muscle strength or a loss of physical performance with increasing rates of disability, poor mobility, frailty, and even the mortality and morbidity. Bone and muscle have been increasingly recognized as interacting tissues as a result of the mechanical effects of muscle loading on bone function. Some endocrine disorders are also related to osteoporosis and sarcopenia, e.g. diabetes mellitus, thyroid dysfunction, vitamin D deficiency, insulin-like growth factor-1, growth hormone, sex hormones, cytokine imbalance, obesity and malnutrition. Bone and muscle dysfunction, also characterized by the predominant atrophy of type II fibers together with smaller and fewer mitochondria, are associated with several genetic polymorphisms of the genes such as α-actinin 3, proliferator-activated receptor gamma coactivator 1-alpha, glycine-n-acyltransferase, methyltransferase-like 21C, myostatin, and myocyte enhancer factor 2C (Fig.1). Therefore, the denervation of single muscle fibers reduces type-II fibers, which are gradually replaced by type-I fibers and adipose tissue. SN - 2040-1124 UR - https://www.unboundmedicine.com/medline/citation/31633306/Commentary_on_the_effects_of_RANKL_inhibition_on_bone_mass_and_muscle_strength L2 - https://doi.org/10.1111/jdi.13165 DB - PRIME DP - Unbound Medicine ER -